Current Headlines

  1. Novartis, University Of Pennsylvania To Build Center For CAR Research

    Novartis and the University of Pennsylvania announced their plans to build the Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

  2. Asterias Biotherapeutics, Cancer Research UK To Conduct Clinical Trial Of Lung Cancer Immunotherapy Vaccine

    BioTime and its subsidiary Asterias Biotherapeutics announced in a press release that they have agreed to conduct an immunotherapy vaccine trial for lung cancer with Cancer Research UK. The charity’s development and commercialization arm, Cancer Research Technology (CRT), will also participate in the trial of AST-VAC2 in subjects with non-small cell lung cancer. The trial will evaluate toxicity, safety, feasibility, immune response, and clinical outcomes.

  3. New Immunotherapy Vaccine Developed For HER2 Positive Breast Cancer

    Researchers at the University of Texas MD Anderson Cancer Center have developed a new and promising immunotherapy breast cancer vaccine candidate, GP2, which prevents disease recurrence in high-risk patients, especially in combination with a powerful immunotherapy drug.

  4. EMD Serono Collaborates With Accelerated Cure Project For MS Research Study

    EMD Serono last week announced that it has entered an agreement with the Accelerated Cure Project for Multiple Sclerosis (ACP) to help launch a new MS research program called the Optimizing Treatment—Understanding Progression (OPT-UP) study. The collaborative research study will help advance the understanding of and treatment options for MS, which is a disabling neurological disease affecting more than two million people worldwide.

  5. FUJIFILM Diosynth Biotechnologies Chooses ambr250 System For Optimising Microbial Fermentation

    TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, is pleased to announce that its ambr250 automated mini bioreactor system is being successfully used at leading Contract Development and Manufacturing Organisation, FUJIFILM Diosynth Biotechnologies, for optimising their microbial fermentations to accelerate scale-up production of protein-based therapeutics.

  6. Google’s Calico Enters R&D Partnership To Tackle Brain Disorders

    Google’s life sciences startup Calico announced that it has signed a research and development partnership to tackle neurodegenerative disorders caused by the deterioration and death of nerve cells.

  7. Genocea Kicks Off Phase 2 Trial For Pneumococcus Vaccine

    Clinical stage biopharmaceutical firm Genocea announced that it has started the Phase 2A trial for GEN-004, its universal vaccine candidate against pneumococcus.

  8. Burnet Scientists ID Proteins For Malaria Vaccines

    The Burnet Institute reported that several of its researchers have identified a group of proteins that has the potential to be the cornerstone of new diagnostics and vaccines against malaria.

  9. CDMO Patheon To Manufacture Novel Polymer For Relypsa

    Relypsa, Inc. announced in a press release that it has engaged Patheon, a contract development and manufacturing organization (CDMO), to produce patiromer, a novel polymer. The multi-year commercial manufacturing and supply agreement with Patheon is for the finished product manufacture of the agent to treat hyperkalemia. Relypsa plans to name Patheon as the manufacturer in its New Drug Application (NDA) to the Food and Drug Administration (FDA). Wilhelm Stahl, Ph.D., SVP of Pharmaceutical Operations at Relypsa, said, “Having multiple, well-respected and proven global pharmaceutical suppliers gives us confidence in meeting potential demand and providing a high quality product to patients."

  10. Experimental Stem Cell Treatment Cleared For First Human Trial

    Japanese researchers at the RIKEN Center for Developmental Biology (CDB) have prepared a potential treatment using stem cells to treat degenerative eye diseases, and they are set to begin testing the treatment on the first human patient very soon.